DBV Technologies account plan
Food allergy skin patch
At a glance
DBV Technologies is a French late-stage biopharma developing the Viaskin Peanut patch, with a BLA filed at the FDA in September 2026.
DBV Technologies is a late-stage specialty biopharmaceutical company headquartered in Châtillon, France, with North American operations in Warren, New Jersey. It develops one platform, Viaskin, a skin patch that delivers allergen through intact skin (epicutaneous immunotherapy, EPIT), aimed first at children with peanut allergy. It reports one operating segment and had no revenue in 2025; its FY2025 net loss was $146.9 million and it had 125 full-time employees at December 31, 2025. Its ordinary shares are listed on Euronext Paris and its ADSs on the Nasdaq Capital Market. Clinical trials are run by CROs and patches are made by contract manufacturers.
Business units
Viaskin Peanut Patch (DBV712)
about 94% of FY2025 R&D excluding share-based compensation ($107.2 million)The lead candidate, evaluated in twelve completed clinical trials and holding FDA Breakthrough Therapy designation in children. A BLA for children aged 4-7, backed by the Phase 3 VITESSE trial (46.6% responders vs 14.8% on placebo), was submitted to the FDA on September 30, 2026 with a Priority Review request. A BLA for toddlers aged 1-3 is planned for the second half of 2026, conditional on the COMFORT Toddlers safety study.
Viaskin Milk (DBV135)
$0.2 million of R&D in 2025A patch for IgE-mediated cow's milk protein allergy in children aged 2 to 17, with FDA Fast Track designation. Spending fell from $3.6 million in 2024 as resources went to peanut; DBV intends to discuss future trial designs with regulators.
Other platform applications and biomarkers
$7.0 million of other R&D in 2025Human proof-of-concept trials of Viaskin in eosinophilic esophagitis and as a pertussis booster vaccine in adults, plus biomarker research with academic partners to identify early responders to Viaskin Peanut. DBV may seek selective partnerships for indications outside food allergy.
Strategic priorities
- US approval of Viaskin Peanut for children 4-7
- The BLA was submitted on September 30, 2026 after FDA feedback on the organisation and formatting of CMC and biostatistical data moved it from the second to the third quarter of 2026; the FDA did not request additional data. DBV requested Priority Review, which would take six months once the file is accepted.
- Toddler (1-3) BLA
- A BLA under an Accelerated Approval pathway is planned for the second half of 2026, conditional on COMFORT Toddlers, whose recruitment closed in the second quarter of 2026.
- Building a US commercial organisation
- DBV is investing in market access, patient services, brand readiness, field force planning and launch operations; Kevin Trapp was appointed Chief Commercial Officer on November 3, 2025. The 10-K sizes the opportunity at about 670,000 US children aged 1 to 7 with peanut allergy and about 4,500 US allergists.
- European resubmission
- EMA scientific advice indicated that EPITOPE plus a positive VITESSE, with a new toddler safety study, could support an MAA for ages 1-7; DBV intends to resubmit once that data set is available.
- Extending the platform to infants
- The Phase 2 THRIVE study in infants aged 6 through 12 months screened its first participant on June 2, 2026.
Latest results
DBV generated no revenue in the first half of 2026. Its H1 2026 net loss was $98.0 million (H1 2025: $69.0 million), with R&D up 17% to $64.6 million, sales and marketing at $10.4 million (H1 2025: $0.7 million) and G&A up 78% to $25.1 million as it builds US commercial infrastructure. Average headcount rose to 170 in H1 2026 from 109 a year earlier. Cash and cash equivalents were $174.9 million at June 30, 2026, and after the BLA delay management estimates runway into the third quarter of 2027, including cost-containment measures.
Investments and deals
- 2025 PIPE and ATM financing
- Initial PIPE gross proceeds of $125.5 million in April 2025, followed by $195 million from full warrant exercise after VITESSE; $65 million raised through the ATM programme in the fourth quarter of 2025. The final $94 million of warrant proceeds arrived in January 2026.
- Commercial patch capacity at Fareva Amboise
- A June 25, 2026 letter of intent covers readiness work, equipment upgrades and workforce expansion for commercial patch production: a planned investment of about $7.5 million, of which up to $5.2 million is to be supported by DBV, contingent on FDA approval.
- Peanut Source Material line at Fareva La Vallée
- A dedicated production line with technology transfer from Sanofi, under a manufacturing and supply agreement effective March 17, 2026, exclusive to DBV for eight years.
- US distribution services
- A June 5, 2026 letter of intent with ICS for US commercialisation support and distribution services if the product is approved.
Challenges and risks
- Single-source manufacturing under FDA scrutiny
- The FDA has issued warning letters to Fareva Amboise, DBV's sole patch manufacturer, citing cGMP deficiencies; DBV has no readily available alternative source, and Sanofi is the only API manufacturer.
- Cash burn before any revenue
- Operating cash use was $101.7 million in H1 2026, the accumulated deficit reached $1,553 million at the end of 2025, and no ATM sales are possible until a new Form S-3 is effective.
- Regulatory history
- A BLA was withdrawn in 2018, a Complete Response Letter asking for CMC data followed in August 2020, and the EU MAA was withdrawn in 2021.
- Building commercial capabilities from scratch
- DBV must build sales, marketing, distribution and market access, and has not finalised a price; Xolair is priced from around $10,000 into the $30,000s in this age range.
What leadership says
“2026 is and will continue to be a pivotal year for DBV. We are working aggressively to transform the company into a commercial organization in anticipation of the potential approval of the Viaskin Peanut patch for children aged four through seven by the FDA.”
“The submission of our BLA brings VIASKIN Peanut Patch, a non-invasive, practical treatment option, one step closer to being available for children ages 4 through 7 living with peanut allergy, and marks a significant milestone in DBV's transformation into a commercial organization”
“It's certainly a tremendous amount of work to move from the clinical to commercial stage.”
Where a supplier can help
- Launch operations and market access
- Tied to the US commercial build-out: DBV is investing in market access, patient services, brand readiness and field force planning ahead of a potential approval, which opens room for launch, payer and patient-services partners.
- Quality and cGMP remediation support
- Tied to the Fareva warning letters: DBV is working with its sole patch manufacturer on remediation, where quality, compliance and supply-chain expertise could reduce approval risk.
- Regulatory submission tooling
- Tied to the BLA delay: FDA feedback concerned the organisation, mapping and formatting of CMC and biostatistical data sets, and the toddler BLA is still to come, so regulatory publishing and data-management support is relevant.
- Cost-conscious back-office scaling
- Tied to cash burn and cost containment: G&A and headcount are rising while runway is set into the third quarter of 2027, so offers that scale HR, IT, finance or compliance without fixed cost fit the budget discipline DBV describes.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like DBV Technologies?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report on Form 10-K for the fiscal year ended December 31, 2025
- DBV Technologies is a French (Châtillon) late-stage specialty biopharmaceutical company, listed on Euronext Paris and Nasdaq, built on one platform: Viaskin, an epicutaneous patch delivering allergen through intact skin (epicutaneous immunotherapy, EPIT). It reports one operating segment and had no revenue in 2025 or 2024.
- Lead asset Viaskin Peanut Patch: positive Phase 3 VITESSE topline in children 4-7 (December 16, 2025): 46.6% responders vs 14.8% on placebo, lower bound of the 95% CI 24.5% vs a 15% threshold. BLA for ages 4-7 planned for the first half of 2026; BLA for toddlers 1-3 (Accelerated Approval pathway) planned for the second half of 2026, conditional on the COMFORT Toddlers safety study.
- FY2025: net loss $146.9 million (2024: $113.9 million); R&D $116.7 million (+31%), of which $16.1 million of pre-commercial inventory written down; G&A $32.8 million; sales and marketing $3.2 million; research tax credit $5.6 million.
- Cash $194.2 million at December 31, 2025 (vs $32.5 million); 2025 financing of $276.2 million (2025 PIPE and ATM program), plus $94 million of warrant exercise proceeds received in January 2026. Runway into the second quarter of 2027; the going-concern doubt was lifted.
- Pivot to commercial: US launch plan targets about 4,500 allergists with a 50 to 70 person specialty sales force and 8 to 10 account managers covering about 50 payers; an estimated 670,000 US children aged 1 to 7 have peanut allergy. Kevin Trapp joined as Chief Commercial Officer (November 2025).
- Supply chain run by partners: Sanofi (Viaskin Peanut API, agreement updated August 2025, 4-year term), Fareva Amboise (sole patch manufacturer) and Fareva La Vallée (peanut source material, agreement effective March 17, 2026).
- Competitive context: Palforzia (oral immunotherapy) is to be discontinued by Stallergenes Greer on July 31, 2026; Xolair approved for food allergy in February 2024; GSK's ozureprubart (via RAPT Therapeutics) a possible future competitor.
- Key risks: dependence on a single platform and product, FDA approval, single-source manufacturing, need for additional funding, and building sales and distribution from scratch.
- Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 (Q2 and H1 2026)
- BLA for the Viaskin Peanut patch in children 4-7 moved from the second to the third quarter of 2026 to fold in FDA feedback on the organisation, mapping and formatting of existing CMC and biostatistical data; the FDA did not request any additional data. The toddler (1-3) BLA is still planned for the second half of 2026.
- No revenue. H1 2026 net loss $98.0 million (H1 2025: $69.0 million); Q2 2026 net loss $50.4 million.
- H1 2026 operating expenses $100.1 million (+43%): R&D $64.6 million (+17%), sales and marketing $10.4 million (vs $0.7 million), G&A $25.1 million (+78%), reflecting the US commercial build-out.
- Cash $174.9 million at June 30, 2026 (December 31, 2025: $194.2 million), runway into the third quarter of 2027 after cost-containment measures. The ATM programme cannot be used until a new Form S-3 is effective.
- Average headcount rose to 170 in H1 2026 from 109 in H1 2025, mostly in the US.
- Launch readiness: a letter of intent with Fareva for commercial-scale patch manufacturing (planned investment about $7.5 million, of which up to $5.2 million supported by DBV); a letter of intent with ICS for US distribution; an 8-year peanut source material supply agreement with Fareva La Vallée.
- Clinical: COMFORT Toddlers recruitment closed; Phase 2 THRIVE started in infants aged 6-12 months.
- New risk: the FDA has issued warning letters to Fareva Amboise, DBV's sole patch manufacturer, citing cGMP deficiencies, which could affect BLA timing.
- DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN Peanut Patch in Children Aged 4-7 Years
- DBV has submitted its Biologics License Application (BLA) to the US FDA for the VIASKIN Peanut Patch in children aged 4 through 7 with peanut allergy. The submission lands in the third quarter of 2026, as guided in July.
- DBV has requested Priority Review. The FDA previously granted the patch Breakthrough Therapy Designation.
- The BLA rests on the Phase 3 VITESSE trial: 654 children randomised 2:1 at 86 sites in the US, Canada, the UK, Europe and Australia. DBV calls it the largest immunotherapy trial to date in this population.
- CEO Daniel Tassé: the BLA "marks a significant milestone in DBV's transformation into a commercial organization".
- Ongoing programmes cover toddlers (1 through 3) and children (4 through 7). DBV is headquartered in Châtillon, France, with North American operations in Warren, NJ.
- DBV Technologies Q2 2026 Results and Business Update Conference Call
- Tassé: "2026 is and will continue to be a pivotal year for DBV. We are working aggressively to transform the company into a commercial organization" ahead of potential FDA approval of the Viaskin Peanut patch in children aged 4-7.
- The BLA delay is about formatting, not data: "the FDA has not requested additional data". The work is incorporating feedback on the organisation, mapping and formatting of CMC and biostatistics data sets, for an "optimized BLA in Q3 of 2026". Completing those two discussions are the gating items.
- DBV will request Priority Review on the strength of the Breakthrough designation (up to 60 days for acceptance, then a six-month review). Nothing the FDA asked for changes the way the product is manufactured.
- The toddler (1-3) BLA is still targeted "by the end of the year". COMFORT Toddlers is a 6-month safety study, and recruitment has closed.
- CMO Pharis Mohideen: new VITESSE subgroup data, and the Phase 2 THRIVE study in infants aged 6-12 months started; a new study confirms US pediatric peanut allergy prevalence of about 2%.
- CCO Kevin Trapp: investing in market access, patient services, brand readiness, field force planning and launch operations; Xolair prices in this age range run from about $10,000 into the $30,000s; DBV has tested a range of prices but has not finalised one.
- Funded into Q3 2027. Investment decisions are tied to "disciplined capital allocation".
Questions about DBV Technologies
What does DBV Technologies do?
DBV develops Viaskin, a skin patch that delivers allergen through intact skin to treat food allergy. Its lead product, the Viaskin Peanut patch, targets children with peanut allergy; no DBV product is yet authorised for sale.
Does DBV Technologies have revenue?
No. DBV had no revenue in 2025 or H1 2026; it reported a FY2025 net loss of $146.9 million and an H1 2026 net loss of $98.0 million, and had $174.9 million of cash at June 30, 2026.
How many employees does DBV Technologies have?
DBV had 125 full-time employees at December 31, 2025, and an average headcount of 170 in H1 2026.
Who leads DBV Technologies?
Daniel Tassé is Chief Executive Officer, Virginie Boucinha is Chief Financial Officer and Kevin Trapp is Chief Commercial Officer.
What is DBV's strategy?
DBV is turning itself into a commercial company: it filed a BLA for Viaskin Peanut in children 4-7 in September 2026, plans a toddler BLA, and is building US launch capabilities.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)